Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study

World News: . []

"We are very pleased with NeoTX's progress in the ANYARA project. The collaboration with AstraZeneca validates the project and is an important step towards start of the clinical study" says Helén Tuvesson, CEO, Active Biotech AB. See also for NeoTX's communication related to this information.

ANYARA (Naptumumab, Naptumomab estafenatox,) is a tumor targeting immunotherapy that enhances the ability of the immune system to recognize and kill the tumor. ANYARA induces the activation and expansion of specific T cells outside of the tumor microenvironment and redirect the T cells to attack the tumor cells. Preclinical data demonstrate that ANYARA has synergistic effect with checkpoint inhibitors in various tumor models.

Active Biotech has an agreement with NeoTX Therapeutics Ltd since October 2016 for the global development and commercialization of ANYARA for the treatment of cancer.

Hans Kolam, CFOTel +46 46 19 20 44

Active Biotech AB(Corp. Reg. No. 556223-9227)Box 724, SE-220 07 Lund, SwedenTel: +46 (0)46 19 20 00

More news and information about Active Biotech

Published By:

Globe Newswire: 13:01 GMT Monday 11th February 2019

Published: .

Search for other references to "active" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us